Combination opioid analgesics

Pain Physician

Volumn 11, Issue 2, 2008, Pages 201-214

  Smith, Howard S ^a  

^a ALBANY MEDICAL COLLEGE   (United States)

Author keywords

Combination opioid analgesic; Opioid induced hyperalgesia; Pain; Tolerance

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR STIMULATING AGENT; ALPHA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; ANTIINFLAMMATORY AGENT; BACLOFEN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BUPIVACAINE; BUTOXAMINE; CALCIUM CHANNEL BLOCKING AGENT; CANNABINOID RECEPTOR AFFECTING AGENT; CHOLECYSTOKININ RECEPTOR BLOCKING AGENT; CLONIDINE; CODEINE; DEXTROMETHORPHAN PLUS MORPHINE; DRONABINOL; GABAPENTIN; LEVOBUPIVACAINE; LOCAL ANESTHETIC AGENT; LORAZEPAM; LUMIRACOXIB; MORPHINE; MU OPIATE RECEPTOR AGONIST; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NALBUPHINE; NARCOTIC ANALGESIC AGENT; NEUROPEPTIDE FF; NIMODIPINE; PLACEBO; SEROTONIN ANTAGONIST; TAPENTADOL; UNINDEXED DRUG;

ADJUVANT THERAPY; ALLODYNIA; ANALGESIC ACTIVITY; ANALGESIC AGENT ABUSE; ANTINOCICEPTION; AREA UNDER THE CURVE; CANCER PAIN; CHRONIC PAIN; CLINICAL TRIAL; COCAINE DEPENDENCE; COMBINATION CHEMOTHERAPY; CONFUSION; CONSTIPATION; DIABETIC NEUROPATHY; DOSE RESPONSE; DROWSINESS; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE COMPARISON; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG POTENCY; DRUG POTENTIATION; DRUG TOLERANCE; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERALGESIA; INFLAMMATION; MAXIMUM TOLERATED DOSE; MONOTHERAPY; NAUSEA; NAUSEA AND VOMITING; NEUROPATHIC PAIN; NONHUMAN; PAIN; PATIENT COUNSELING; PATIENT SATISFACTION; POSTHERPETIC NEURALGIA; REVIEW; SEDATION; SIDE EFFECT; TRIGEMINUS NEURALGIA; VOMITING; XEROSTOMIA;

EID: 42249100977     PISSN: 15333159     EISSN: None     Source Type: Journal    
DOI: 10.36076/ppj.2008/11/201     Document Type: Review

References (80)

1. Le Guen S, Mas Nieto M, Canestrelli C, Chen H, Fournié-Zaluski MC, Cupo A, Maldonado R, Roques BP, Noble F. Pain management by a new series of dual inhibitors of enkephalin degrading enzymes: Long lasting antinociceptive properties and potentiation by CCK2 antagonist or methadone. Pain 2003; 104:139-148.
2. Chen H, Noblr F, Roques BP, Fournié-Zaluski MC. Long lasting antinociceptive properties of enkephalin degrading enzyme (NEP and APN) inhibitor prodrugs. J Med Chem 2001; 44:3523-3530.
3. Tai YH, Wang YH, Wang JJ, Tao PL, Tung CS, Wong CS. Amitriptyline suppresses neuroinflammation and up-regulates glutamate transporters in morphinetolerant rats. Pain 2006; 124:77-86.
4. Ortiz MI, Castaneda-Hernández G. Examination of the interaction between peripheral lumiracoxib and opioids on the 1% formalin test in rats. Eur J Pain 2008; 12:233-241.
5. Eckhardt K, Ammon S, Hofmann U, Riebe A, Gugeler N, Mikus G. Gabapentin enhances the analgesic effect of morphine in healthy volunteers. Anesth Analg 2000; 91:185-191.
6. Gilron I, Bailey JM, Tu D, Holden RR, Weaver DF, Houlden RL. Morphine, gabapentin, or their combination for neuropathic pain. Engl J Med 2005; 352:1324-1334.
7. Keskinbora K, Pekel AF, Aydinli I. Gabapentin and an opioid combination versus opioid alone for the management of neuropathic cancer pain: A randomized open trial. J Pain Symptom Manage 2007; 34:183-189.
8. Maves TJ, Gebhart GF. Analgesic synergy between intrathecal opioids and local anesthetics. Anesth Analg 1991; 73:365-366.
9. Komai H, McDowell TS. Effects of local anesthetics on opioid inhibition of calcium current in rat dorsal root ganglion neurons. Neurosci Lett 2007; 418:298-303.
10. Yanagidate F, Strichartz GR. Bupivacaine inhibits activation of neuronal spinal extracellular receptor-activated kinase through selective effects on ionotropic receptors. Anesthesiology 2006; 104:805-814.
11. Smith HS. Combination opioid analgesics. Presented at the Capital District Pain Meeting. June 2007. Albany, NY.
12. Saito Y, Kaneki M, Kirihara Y, Sakura S, Kosaka Y. Interaction of intrathecally infused morphine and lidocaine in rats (part II): Effects on the development of tolerance to morphine. Anesthesiology 1998; 89:1464-1470.
13. van Dongen RT, Crul BJ, van Egmond J. Intrathecal coadministration of bupivacaine diminished morphine dose progression during long-term intrathecal infusion in cancer patients. Clin J Pain 1999; 15:166-172.
14. Mercadante S, Intravaia G, Villari P, Ferrera P, Riina S, David F, Mangione S. Intrathecal treatment in cancer patients unresponsive to multiple trials of systemic opioids. Clin J Pain 2007; 23:793-798.
15. Fairbanks CA, Wilcox GL. Spinal antinociceptive synergism between morphine and clonidine persists in mice made acutely or chronically tolerant to morphine. J Pharmacol Exp Ther 1999; 288:1107-1116.
16. Gupta H, Verma D, Ahuja RK, Srivastava DN, Wadhwa S, Ray SB. Intrathecal co-administration of morphine and nimodipine produces higher antinociceptive effect by synergistic interaction as evident by injecting different doses of each drug in rats. Eur J Pharmacol 2007; 561:46-53.
17. Cox ML, Haller VL, Welch SP. Synergy between delta9-tetrahydrocannabinol and morphine in the arthritic rat. Eur J Pharmacol 2007; 567:125-130.
18. Smith PA, Selley DE, Sim-Selley LJ, Welch SP. Low dose combination of morphine and delta9-tetrahydrocannabinol circumvents antinociceptive tolerance and apparent desensitization of receptors. Eur J Pharamcol 2007; 571:129-137.
19. Narang S, Gibson D, Wasan AD, Ross EL, Michna E, Nedeljkovic SS, Jamison RN. Efficacy of Dronabinol as an adjuvant treatment for chronic pain patients on opioid therapy. J Pain 2007; in press.
20. Powell KJ, Ma W, Sutak M, Doods H, Quirion R, Jhamandas K. Blockade and reversal of spinal morphine tolerance by peptide and non-peptide calcitonin gene-related peptide receptor antagonists. Br J Pharmacol 2000; 131:875-884.
21. Trang T, Sutak M, Quirion R, Jhamandas K. The role of spinal neuropeptides and prostaglandins in opioid physical dependence. Br J Pharmacol 2002; 136:37-48.
22. Trang T, Sutak M, Jhamandas K. Involvement of cannabinoid (CB1)-receptors in the development and maintenance of opioid tolerance. Neuroscience 2007; 146:1275-1288.
23. Roberts DC, Brebner K. GABA modulation of cocaine self-administration. Ann NY Acad Sci 2000; 909:145-158.
24. Shoptaw S, Yang X, Rotheram-Fuller EJ, Hsieh YC, Kintaudi PC, Charuvastra VC, Ling W. Randomized placebo-controlled trial of baclofen for cocaine dependence: Preliminary effects for individuals with chronic patterns of cocaine use. J Clin Psychiatry 2003; 64:1440-1448.
25. Potes CS, Neto FL, Castro-Lopes JM. Inhibition of pain behavior by GABA(B) receptors in the thalamic ventrobasal complex: Effect on normal rats subjected to the formalin test of nociception. Brain Res 2006; 1115:37-47.
26. Potes CS, Neto FL, Castro-Lopes JM. Administration of baclofen, a gamma-aminobutyric acid type B agonist in the thalamic ventrobasal complex, attenuates allodynia in monoarthritic rats subjected to the ankle-bend test. J Neurosci Res 2006; 83:515-523.
27. Steardo L, Leo A, Marano E. Efficacy of baclofen in trigeminal neuralgia and some other painful conditions. A clinical trial. Eur Neurol 1984; 23:51-55.
28. Sindrup SH, Jensen TS. Pharmacotherapy of trigeminal neuralgia. Clin J Pain 2002; 18:22-27.
29. Fromm GH, Terrence CF, Chatta AS. Baclofen in the treatment of trigeminal neuralgia: Double-blind study and long-term follow-up. Ann Neurol 1984; 15:240-244.
30. Hara K, Saito Y, Kirihara Y, Yamada Y, Sakura S, Kosaka Y. The interaction of antinociceptive effects of morphine and GABA receptor agonists within the rat spinal cord. Anesth Analg 1999; 89:422-427.
31. Fromm GH, Terrence CF. Comparison of L-baclofen and racemic baclofen in trigeminal neuralgia. Neurology 1987; 37:1725-1728.
32. Hosny A, Simopoulos T, Collins B. Response of intractable post herpetic neuralgia to intrathecal baclofen. Pain Physician 2004; 7:345-347.
33. Slonimski M, Abram SE, Zungia RE. Intrathecal baclofen in pain management. Reg Anesth Pain Med 2004; 29:369-376.
34. Addolorato G, Leggio L, Abenavoli L, Agabio R, Caputo F, Capristo E, Colomb G, Luigi Gessa G, Gasbarrini Giovanni. Baclofen in the treatment of alcohol withdrawal syndrome: A comparative study vs diazepam. Am J Med 2006; 119:276.e13-18.
35. Akhondzadeh S, Ahmadi-Abhari SA, Assadi SM, Shabestari OL, Kashani AR, Farzanehgan ZM. Double-blind randomized controlled trial of baclofen vs. clonidine in the treatment of opiates withdrawal. J Clin Pharm Ther 2000; 25:347-353.
36. Suzuki T, Nurrochmad A, Ozaki M, Khotib J, Nakamura A, Imai S, Shibasaki M, Yajima Y, Narita M. Effect of a selective GABA(B) receptor agonist baclofen on the mu-opioid receptor agonist-induced antinociceptive, emetic and rewarding effects. Neuropharmacology 2005; 49:1121-1131.
37. Mika J, Osikowicz M, Makuch W, Przewlocka B. Minocycline and pentoxifylline attenuate allodynia and hyperalgesia and potentiate the effects of morphine in rat and mouse models of neuropathic pain. Eur J Pharmacol 2007; 560:142-149.
38. Kraus J, Borner C, Giannini E, Hickfang K, Braun H, Mayer P, Hoehe MR, Ambrosch A, Konig W, Hollt V. Regulation of mu-opioid receptor gene transcription by interleukin-4 and influence of an allelic variation within a STAT6 transcription factor binding site. J Biol Chem 2001; 276:43901-43908.
39. Börner C, Wöltje M, Höllt V, Krause J. STAT6 transcription factor binding sites with mismatches within the canonical 5′TTC...GAA-3′ motif involved in regulation of delta- and mu-opioid receptors. J Neurochem 2004; 91:1493-1500.
40. Börner C, Stumm R, Höllt V, Kraus J. Comparative analysis of mu-opioid receptor expression in immune and neuronal cells. J Neuroimmunol 2007; 188:56-63.
41. Singal A, Anjaneyulu M, Chopra K. Modulatory role of green tea extract on antinociceptive effect of morphine in diabetic mice. K. Med Food 2005; 8:386-391.
42. Yoshikawa M, Ito K, Maeda M, Akahori K, Takahashi S, Jin XL, Matsuda M, Suzuki T, Oka T, Kobayashi H, Hashimoto A. Activation of supraspinal NMDA receptors by both D-serine alone or in combination with morphine leads to the potentiation of antinociception in tail-flick test of rats. Eur J Pharmacol 2007; 565:89-97.
43. Ugolini G, Marinelli S, Covaceuszach S, Cattaneo A, Pavone F. The function neutralizing anti-TrkA antibody MNAC13 reduces inflammatory and neuropathic pain. Proc Natl Acad Sci USA 2007; 104:2985-2990.
44. Gordon S, Coletti D, Bergman S, Shimizu N, Caccamese J, Laska G, Lee V, Schmidt W, Robbins W. LNS5662 (Flavonal-PGP Modulator) ameliorates CNS effects of oxycodone in an acute pain model. J Pain 2007; 8:S45.
45. Cantarella PA, Chahl LA. Acute effects of morphine on substance P concentrations in microdissected regions of guinea-pig brain. Behav Pharmacol 1996; 7:470-476.
46. Wan Q, Douglas SD, Wang X, Kolson DL, O'Donnell LA, Ho WZ. Morphine upregulates functional expression of neurokinin-1 receptor in neurons. J Neurosci Res 2006; 84:1588-1596.
47. Farooqui M, Li Y, Rogers T, Poonawala T, Griffin RJ, Song CW, Gupta K. COX-2 inhibitor celecoxib prevents morphine-induced promotion of angiogenesis, tumour growth, metastasis and mortality, without compromising analgesia. Br J Cancer 2007; 97:1523-1531.
48. King T, Ossipov NH, Vanderah TW, Porreca F, Lai J. Is paradoxical pain induced by sustained opioid exposure an underlying mechanism of opioid antinociceptive tolerance? Neurosignals 2005; 14:194-205.
49. Mao J, Price DP, Mayer DJ. Mechanisms of hyperalgesia and morphine tolerance: A current view of their possible interactions. Pain 1995; 62:259-274.
50. Zeng J, Thomson LM, Aicher SA, Terman GW. Primary afferent NMDA receptors increase dorsal horn excitation and mediate opiate tolerance in neonatal rats. J Neurosci 2006; 26:12033-12042.
51. Galer BS, Lee D, Ma T, Nagle B, Schlagheck TG. MorphiDex (morphine sulfate/dextromethorphan hydrobromide combination) in the treatment of chronic pain: Three multicenter, randomized, double-blind, controlled clinical trials fail to demonstrate enhanced opioid analgesia or reduction in tolerance. Pain 2005; 115:284-295.
52. Xu T, Jiang W, Du D, Xu Y, Hu Q, Shen Q. Role of spinal metabotropic glutamate receptor subtype 5 in the development of tolerance to morphine-induced antinociception in rat. Neurosci Lett 2007; 420:155-159.
53. Shen KF, Crain SM. Ultra-low doses of naltrexone or etorphine increase morphine's antinociceptive potency and attenuate tolerance/dependence in mice. Brain Res 1997; 757:176-190.
54. Webster LR. Oxytrex: An oxycodone and ultra-low-dose naltrexone formulation. Expert Opin Investig Drugs 2007; 16:1277-1283.
55. Shen KF, Crain SM. Cholera toxin-B subunit blocks excitatory opioid receptor-mediated hyperalgesic effects in mice, thereby unmasking potent opioid analgesia and attenuating opioid tolerance/dependence. Brain Res 2001; 919:20-30.
56. Crain SM, Shen KF. Neuraminidase inhibitor, oseltamivir blocks GM1 ganglioside-regulated excitatory opioid receptor-mediated hyperalgesia, enhances opioid analgesia and attenuates tolerance in mice. Brain Res 2004; 995:260-266.
57. Abul-Husn NS, Sutak M, Milne B, Jhamandas K. Augmentation of spinal morphine analgesia and inhibition of tolerance by low doses of mu- and delta-opioid receptor antagonists. Br J Pharmacol 2007; 151:877-887.
58. Xie JY, Herman DS, Stiller CO, Gardell LR, Ossipov MH, Lai J, Porreca F, Vanderah TW. Cholecystokinin in the rostral ventromedial medulla mediates opioid-induced hyperalgesia and Antinociceptive tolerance. J Neurosci 2005; 25:409-416.
59. Suzuki R, Rahman W, Hunt SP, Dickenson AH. Descending facilitatory control of mechanically evoked responses is enhanced in deep dorsal horn neurons following peripheral nerve injury. Brain Res 2004; 1019:68-76.
60. Mitchell JM, Bergren LJ, Chen KS, Fields HL. Cholecystokinin is necessary for the expression of morphine conditioned place preference. Pharmacol Biochem Behav 2006; 85:787-795.
61. Liang DY, Shi X, Li X, Li J, Clark JD. The beta2 adrenergic receptor regulates morphine tolerance and physical dependence. Behav Brain Res 2007; 181:118-126.
62. Suzuki R, Rahman W, Rygh LJ, Webber M, Hunt SP, Dickenson, AH. Spinal-supraspinal serotonergic circuits regulating neuropathic pain and its treatment with gabapentin. Pain 2005; 117:292-303.
63. King T, Gardell LR, Wang R, Vardanyan A, Ossipov MH, Malan TP Jr, Vanderah TW, Hunt SP, Hruby VJ, Lai J, Porreca F. Role of NK-1 neurotransmission in opioid-induced hyperalgesia. Pain 2005; 116:276-288.
64. Vera-Portocarrero LP, Zhang ET, King T, Ossipov MH, Vanderah TW, Lai J, Porreca F. Spinal NK-1 receptor expressing neurons mediate opioid-induced hyperalgesia and antinociceptive tolerance via activation of descending pathways. Pain 2007; 129:35-45.
65. Joshi D, Singh A, Naidu PS, Kulkarni SK. Protective effect of bupropion on morphine tolerance and dependence in mice. Methods Find Exp Clin Pharmacol 2004; 26:623-626.
66. Shu H, Arita H, Hayashida M, Chiba S, Sekiyama H, Hanaoka K. Inhibition of morphine tolerance by processed Aconiti tuber is mediated by kappa-opioid receptors. J Ethnopharmacol 2006; 106:263-271.
67. Jiang J, Huang J, Hong Y. Bovine adrenal medulla 22 reverses antinociceptive morphine tolerance in the rat. Behav Brain Res 2006; 168:167-171.
68. Cai Q, Jiang J, Chen T, Hong Y. Sensory neuron-specific receptor agonist BAM822 inhibits the development and expression of tolerance to morphine in rats. Behav Brain Res 2007; 178:154-159.
69. Haghparast A, Khani A, Naderi N, Alizadeh AM, Motamedi F. Repeated administration of nicotine attenuates the development of morphine tolerance and dependence in mice. Pharmacol Biochem Behav 2007; 88:385-392.
70. Cahill CM, Dray A, Coderre TJ. Intrathecal nerve growth factor restores opioid effectiveness in an animal model of neuropathic pain. Neuropharmacology 2003; 45:543-552.
71. McNaull B, Trang T, Sutak M, Jhamandas K. Inhibition of tolerance to spinal morphine antinociception by low doses of opioid receptor antagonists. Eur J Pharmacol 2007; 560:132-141.
72. Marchand S, Betourne A, Marty V, Doumas S, Halley H, Lassalle JM, Zajac JM, Frances B. A neuropeptide FF agonist blocks the acquisition of conditioned place preference to morphine in C57BI/6J mice. Peptides 2006; 27:964-972.
73. Kotlinska J, Pachuta A, Dylag T, Silberring J. Neuropeptide FF (NPFF) reduces the expression of morphine- but not of ethanol-induced conditioned place preference in rats. Peptides 2007; 28:2235-2242.
74. Wei J, Dong M, Xiao C, Jiang F, Castellino FJ, Prorok M, Dai Q. Conantokins and variants derived from cone snail venom inhibit naloxone-induced withdrawal jumping in morphine-dependent mice. Neurosci Lett 2006; 405:137-141.
75. Kato H, Narita M, Suzuki M, Yoshimoto K, Yasuhara M, Suzuki T. Role of tyrosine kinase-dependent phosphorylation of NR2B subunit-containing NMDA receptor in morphine reward. Nihon Arukoru Yakubutsu Igakkai Zasshi 2007; 42:13-20.
76. Watkins LR, Hutchinson MR, Milligan ED, Maier SF. "Listening" and "talking" to neurons: Implications of immune activation for pain control and increasing the efficacy of opioids. Brain Res Rev 2007; 56:148-169.
77. Hutchinson MR, Bland ST, Johnson KW, Rice KC, Maier SF, Watkins LR. Opioid-induced glial activation: Mechanisms of activation and implications for opioid analgesia, dependence, and reward. Scientific World Journal 2007; 7:98-111.
78. Ledeboaer A, Hutchinson MR, Watkins LR, Johnson KW. Ibudilast (AV-411). A new class therapeutic candidate for neuropathic pain and opioid withdrawal syndromes. Expert Opin Investig Drugs 2007; 16:935-950.
79. Yao L, McFarland K, Fan P, Jiang Z, Ueda T, Diamond I. Adenosine A2a blockade prevents synergy between mu-opiate and cannabinoid CB1 receptors and eliminated heroin-seeking behavior in addicted rats. Proc Natl Acad Sci USA 2006; 103:7877-7882.
80. Regunathan S. Agmatine: biological role and therapeutic potentials in morphine analgesia and dependence. AAPS J 2006; 8:E479-484.